Literature DB >> 24067174

The practical aspects of insulin at high altitude.

Paul Richards1, David Hillebrandt.   

Abstract

With the increasing prevalence of diabetes and current social philosophy of enablement, many more diabetics are travelling to high altitude where the rate of AMS in Type 1 diabetic mountaineers is no different than nondiabetics. Numerous effects of exercise, both degree and duration, dietary change, illness, stress, mountain sickness, counter-regulatory hormones, and altitude increased sympathetic output, and catecholamines have led to conflicting accounts of insulin requirement increasing or decreasing at altitude. Overall, it would appear that the effects of diet and exercise outweigh those of altitude. Good control requires continual insulin dose adjustment with frequent feedback from blood sugar testing, but glucometers can over- or under-read at altitude. Additionally, heat or cold exposure can degrade insulin efficacy; strategies for storing insulin are described.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067174     DOI: 10.1089/ham.2013.1020

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  3 in total

Review 1.  Special Considerations in Medical Screening for Participants in Remote Endurance Events.

Authors:  Jeremy Joslin; Martin D Hoffman; Ian Rogers; Robert M Worthing; Matt Ladbrook; Joshua Mularella
Journal:  Sports Med       Date:  2015-08       Impact factor: 11.136

2.  Managing diabetes at high altitude: personal experience with support from a Multidisciplinary Physical Activity and Diabetes Clinic.

Authors:  Gary Malcolm; Sian Rilstone; Sivasujan Sivasubramaniyam; Carol Jairam; Stephen Chew; Nick Oliver; Neil E Hill
Journal:  BMJ Open Sport Exerc Med       Date:  2017-08-16

3.  Physiological Characteristics of Type 1 Diabetes Patients during High Mountain Trekking.

Authors:  Bartłomiej Matejko; Andrzej Gawrecki; Marta Wróbel; Jerzy Hohendorff; Teresa Benbenek-Klupa; Dorota Zozulińska-Ziółkiewicz; Maciej T Malecki; Tomasz Klupa
Journal:  J Diabetes Res       Date:  2020-09-15       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.